Cancer Immunology and Oncolytic Virology: Technologies and Global Markets http://www.reportlinker.com/p02070062/Cancer-Immunology-and-Oncolytic-Virology-Technologies-and-Global-Markets.html
Advertisement
REPORT HIGHLIGHTS: The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018.
Advertisement
This report provides: An overview of the global market for cancer immunotherapiesAnalyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018.Analyses of factors influencing market demand such as clinical guidelines, demographic changes, and market saturationTechnological discussion including the current state, newly issued patents, and pending applicationsProfiles of leading companies in the industry.
STUDY GOALS AND OBJECTIVES: This report, PHM129A Cancer Immunology and Oncolytic Virology: Technologies and Global Markets provides an overview of the current and potential global market for cancer immunotherapy and virology. The report provides comprehensive information on a number of the most common cancers, highlighting global incidence and prevalence. It identifies the need for more effective drugs for treatment of these diseases. The key objective is to present a comprehensive analysis of the current state of cancer immunotherapy and where this field is going. A second objective is to examine the current state of oncolytic virology and where this nascent field appears to be heading. Important trends in each field, clinical trials and results, new developments and sales forecasts for cancer immunotherapy from 2011 through 2018 are provided in this report. In addition, sales forecasts are presented for oncolytic virology covering the years 2011 through 2023. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the cancer market. The report also addresses opportunities for future players.
REASONS FOR DOING THE STUDY: This study was conducted to provide detailed information regarding the new area of immunology-based treatment options for cancer. There is an increasing need for new and innovative drugs. This young industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer, more efficacious treatment strategies. This study looks at the latest types of treatment strategies based on immunology, as well as the new field of oncolytic virotherapy, a field still in its infancy showing immense promise for the clinical management of cancer.This BCC Research market research report will increase the reader's awareness of current and emerging drugs and technologies for many cancers.
SCOPE OF REPORT: The scope of this study entails the current immunology therapeutics markets for several of the most common cancers. The sectors covered are colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines and other cancer treatment immunology products. Vaccines against HPV and hepatitis B are included; while such vaccines act only indirectly against cancer, they do serve to protect against the disease. Also covered is oncolytic virology, so new that its market tables have been presented separately from the immunotherapy tables. The report also includes discussion of the regulatory environment, current and developing technologies, cancer incidence, market projections and market share, along with latest trends and clinical trials.
INTENDED AUDIENCE: This report is an exhaustive study on the global oncolytic immunotherapy and virology market, with important statistics and analysis on existing drugs, drug candidates in clinical testing, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in oncolytic immunotherapy strategies for several of the most common cancers, and does so from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of oncology products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the sector. This report shows current trends in oncolytic immunotherapy and virology, new developments and revenue prospects for these areas. The report provides market data for 2011 to 2018 for oncolytic immunotherapy, and 2011 to 2023 for cancer virology. It also covers commercial prospects and the likely revenues in both oncolytic immunotherapy and virology.
INFORMATION SOURCES: A number of companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC Research spoke with officials within the industry and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
Chapter- 1: INTRODUCTION 3 STUDY GOALS AND OBJECTIVESREASONS FOR DOING THE STUDYSCOPE OF REPORTINTENDED AUDIENCEINFORMATION SOURCESANALYST CREDENTIALSRELATED BCC RESEARCH REPORTSBCC RESEARCH ONLINE SERVICESDISCLAIMER
Chapter- 2: SUMMARY 2 CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018Figure Summary : CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018
Chapter- 3: OVERVIEW HISTORY AND CURRENT STATE OF CANCER IMMUNOLOGYSUMMARY OF GLOBAL HUMAN CANCER TRENDS THROUGH 2018
Chapter- 4: OVERVIEW OF CANCER IMMUNOTHERAPY MECHANISMS OF ACTIONBIOLOGICAL RESPONSE MODIFIERSCANCER VACCINESOTHER IMMUNOTHERAPY PRODUCTS FOR CANCER TREATMENTEXPANDED INFORMATION REGARDING SELECTED CLINICAL TRIALS
Chapter- 5: ONCOLYTIC VIROTHERAPY VIROTHERAPYONCOLYTIC VIROLOGYNEWS AND DEALS IN CANCER IMMUNOTHERAPY AND VIROLOGYGOVERNMENT REGULATIONSINDUSTRY STRUCTURE
Chapter- 6: MAJOR MARKETSMARKET FOR ONCOLYTIC VIROLOGY PRODUCTSTable 32 : GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018Table 33 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018Table 34 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018Table 35 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018Table 36 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018Table 37 : VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018)Table 38 : CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018Table 39 : CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 40 : CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 41 : CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 42 : CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 43 : CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 44 : CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 45 : CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 46 : CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 47 : CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 48 : CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018Table 49 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018Table 50 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018Table 51 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018Table 52 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018Table 53 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018Table 54 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018
Chapter- 7: TECHNOLOGY PRODUCTION OF MONOCLONAL ANTIBODIESPATENT EVALUATION
Chapter- 8: COMPANY PROFILES
SELECTED COMPANY PROFILES
List of Tables: CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018Table 1 : GLOBAL PROSTATE CANCER INCIDENCE AND MORTALITY, 2012Table 2 : GLOBAL LEUKEMIA INCIDENCE AND MORTALITY, 2012Table 3 : GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2012Table 4 : BREAST CANCER INCIDENCE, 2012Table 5 : PROGNOSIS OF BREAST CANCER BASED UPON STAGETable 6 : GLOBAL MELANOMA CANCER INCIDENCE AND MORTALITY, 2012Table 7 : GLOBAL OVARIAN CANCER INCIDENCE AND MORTALITY, 2012Table 8 : RELATIVE FIVE-YEAR SURVIVAL RATE FOR INVASIVE EPITHELIAL OVARIAN CANCERTable 9 : GLOBAL CERVICAL CANCER INCIDENCE AND MORTALITY, 2012Table 10 : AVASTIN SALES AND FORECAST, THROUGH 2018Table 11 : FIVE-YEAR RELATIVE SURVIVAL OF CERVIX UTERI CANCER PATIENTS, BASED ON STAGE AT DIAGNOSISTable 12 : GLOBAL LUNG CANCER INCIDENCE AND MORTALITY, 2012Table 13 : STAGES OF LUNG CANCERTable 14 : NON-SMALL CELL LUNG CANCER FIVE-YEAR SURVIVAL RATES BY STAGETable 15 : GLOBAL BRAIN CANCER INCIDENCE AND MORTALITY, 2012Table 16 : GLOBAL MULTIPLE MYELOMA CANCER INCIDENCE AND MORTALITY, 2012Table 17 : GLOBAL PANCREATIC CANCER INCIDENCE AND MORTALITY, 2012Table 18 : EXOCRINE PANCREATIC CANCER FIVE-YEAR SURVIVAL RATETable 19 : GLOBAL HUMAN CANCER TRENDS, 2011-2018Table 20 : U.S. HUMAN CANCER TRENDS, 2011-2018Table 21 : CANADIAN HUMAN CANCER TRENDS, 2011-2018Table 22 : EUROPEAN HUMAN CANCER TRENDS, 2011-2018Table 23 : JAPANESE HUMAN CANCER TRENDS, 2011-2018Table 24 : REST OF WORLD HUMAN CANCER TRENDS, 2011-2018Table 25 : KNOWN OCCUPATIONAL EXPOSURE RISKS ASSOCIATED WITH CANCERTable 26 : COLONY-STIMULATING FACTORS ON THE MARKETTable 27 : SELECTED INTERFERON PRODUCTS ON THE MARKETTable 28 : SELECTED DEVELOPMENTS IN INTERLEUKINS FOR CANCER THERAPYTable 29 : SELECTED APPROVED MONOCLONAL ANTIBODIESTable 30 : ELECTED MABS IN CLINICAL TESTING FOR INITIAL APPROVAL OR FOR ADDITIONAL INDICATIONSTable 31 : SELECTED CLINICAL TRIALS OF IMMUNOTHERAPY PRODUCTSTable 32 : GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018Table 33 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018Table 34 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018Table 35 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018Table 36 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018Table 37 : VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018)Table 38 : CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018Table 39 : CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 40 : CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 41 : CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 42 : CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 43 : CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 44 : CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 45 : CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 46 : CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 47 : CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018Table 48 : CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018Table 49 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018Table 50 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018Table 51 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018Table 52 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018Table 53 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018Table 54 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018Table 55 : GLOBAL ONCOLYTIC VIROTHERAPY MARKET, THROUGH 2023Table 56 : ONCOLYTIC VIROTHERAPY MARKET BY REGION, THROUGH 2023Table 57 : ONCOLYTIC VIROLOGY OUTLOOK BY CANCER TYPE, THROUGH 2023Table 58 : SELECTED PATENTS IN CANCER IMMUNOLOGY AND VIROLOGY, 2005 TO 2013
List of Figures: CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018Figure 1 : GLOBAL HUMAN CANCER TRENDS, 2011-2018Figure 2 : MARKET SHARES OF LEADERS IN CANCER IMMUNOLOGY, 2013
To order this report: Cancer Immunology and Oncolytic Virology: Technologies and Global Markets http://www.reportlinker.com/p02070062/Cancer-Immunology-and-Oncolytic-Virology-Technologies-and-Global-Markets.html
__________________________Contact Clare: [email protected] US: (339)-368-6001Intl: +1 339-368-6001
SOURCE Reportlinker
